Epoetin alfa - Biologic Drug Details

✉ Email this page to a colleague

Summary for epoetin alfa

Tradenames:	2
High Confidence Patents:	5
Applicants:	2
BLAs:	2
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for epoetin alfa
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for epoetin alfa

Recent Clinical Trials for epoetin alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yonsei University	Phase 4
Second Xiangya Hospital of Central South University	Phase 4
Medical Research Future Fund (MRFF)	Phase 3

See all epoetin alfa clinical trials

Recent Litigation for epoetin alfa

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Upsher-Smith Laboratories, LLC v. Xiamen LP Pharmaceutical Co., Ltd.	2023-02-23
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.	2023-01-19
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC.	2021-07-28

See all epoetin alfa litigation

Pharmacology for epoetin alfa

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for epoetin alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for epoetin alfa Derived from Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	⤷ Sign Up	2012-08-15	Company disclosures
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	⤷ Sign Up	2013-08-20	Company disclosures
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	⤷ Sign Up	2003-12-13	Company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for epoetin alfa Derived from Patent Text Search

These patents were obtained by searching patent claims